SCHEMBL438437

SCHEMBL438437

CC(C)(C)OC(=O)N1CCC(NC(=O)C(F)(F)F)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.65
ALDH1A1 P00352 4/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
NPC1 O15118 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49
HPGD P15428 1/20 0.49
HDAC4 P56524 1/20 0.48
EPHX2 P34913 3/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
RECQL P46063 1/20 0.47
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2515885 0.94 EPHX1 (0.67) EPHX1ALDH1A1L3MBTL1NPC1MAPT
SCHEMBL2515884 0.94 EPHX1 (0.67) EPHX1ALDH1A1L3MBTL1NPC1MAPT
SCHEMBL6865392 0.91 EPHX1 (0.55) EPHX1ALDH1A1L3MBTL1NPC1MAPT
SCHEMBL24817359 0.91 EPHX1 (0.55) EPHX1ALDH1A1L3MBTL1NPC1MAPT
SCHEMBL1457410 0.91 EPHX1 (0.55) EPHX1ALDH1A1L3MBTL1NPC1MAPT
SCHEMBL10200817 0.88 EPHX1 (0.68) EPHX1ALDH1A1L3MBTL1NPC1MAPT
SCHEMBL15885465 0.84 EPHX1 (0.46) EPHX1HPGDHDAC4CA1CA2
SCHEMBL30812330 0.84 EPHX1 (0.48) EPHX1ALDH1A1L3MBTL1NPC1MAPT
SCHEMBL555950 0.83 USP30 (0.54) EPHX1ALDH1A1MAPTHPGDHDAC4
SCHEMBL8273736 0.83 USP30 (0.54) EPHX1ALDH1A1MAPTHPGDHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11732259-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2023-08-22 US disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023066363-A1 PARP-1 DEGRADATION AGENT AND USE THEREOF 海思科医药集团股份有限公司 2023-04-27 WO disclosed
US-20210139897-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS SAREPTA THERAPEUTICS, INC. 2021-05-13 US disclosed
US-20210139896-A1 Peptide Oligonucleotide Conjugates JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2021-05-13 US disclosed
US-10760078-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups SAREPTA THERAPEUTICS, INC. (US) 2020-09-01 US disclosed
US-20190218551-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2019-07-18 US disclosed
US-9469664-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups SAREPTA THERAPEUTICS, INC. (US) 2016-10-18 US disclosed
US-9161948-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2015-10-20 US disclosed
US-20150073140-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS SAREPTA THERAPEUTICS, INC. (US) 2015-03-12 US disclosed
EP-2366699-B1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2013-08-07 EP disclosed
US-20120289457-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES AVI BIOPHARMA, INC. (US) 2012-11-15 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-20120065169-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2012-03-15 US disclosed
EP-2366699-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2011-09-21 EP disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
WO-2010038465-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2010-04-08 WO disclosed
US-6235731-B1 REDUCING BLOOD LIPIDS, SUGARS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-22 US disclosed
EP-0915888-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS Takeda Chemical Industries, Ltd. (JP) 1999-05-19 EP disclosed
WO-1997040051-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218551-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB EPHX1 3892/4885ALDH1A1 2803/4885L3MBTL1 15/4885
US-20120065169-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB EPHX1 3892/4885ALDH1A1 2803/4885L3MBTL1 15/4885
US-10760078-B2 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups NSUN2, UPF1, RTCB EPHX1 3892/4885ALDH1A1 2803/4885L3MBTL1 15/4885
US-20210139896-A1 Peptide Oligonucleotide Conjugates SNRPE, SMN1; SMN2, UPF1 EPHX1 4320/4885ALDH1A1 3700/4885L3MBTL1 36/4885
US-20150073140-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB EPHX1 3892/4885ALDH1A1 2803/4885L3MBTL1 15/4885
US-20210139897-A1 OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS NSUN2, UPF1, RTCB EPHX1 3892/4885ALDH1A1 2803/4885L3MBTL1 15/4885
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 EPHX1 2140/4885ALDH1A1 1380/4885L3MBTL1 273/4885
US-20120289457-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES SNRPE, SMN1; SMN2, UPF1 EPHX1 4320/4885ALDH1A1 3700/4885L3MBTL1 36/4885
US-11732259-B2 Peptide oligonucleotide conjugates SNRPE, SMN1; SMN2, UPF1 EPHX1 4320/4885ALDH1A1 3700/4885L3MBTL1 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.